Table 1. Fragments resulting from prediction clustering
Fragment |
Start * |
End* |
Predicted sites† |
Activity‡ |
hA1 |
–28,992 |
–28,221 |
DR4, ER8 |
No |
hA2 |
–27,545 |
–27,013 |
ER7 |
No |
hA3 |
–25,028 |
–24,453 |
ER7(2x) |
No |
hA4 |
–24,213 |
–23,631 |
ER6 |
No |
hA5 |
–22,915 |
–21,663 |
DR5, ER6, ER7(2x) |
No |
hA6 |
–21,183 |
–19,038 |
DR4, DR5(2x), ER7 |
Yes |
hA7 |
–19,275 |
–18,308 |
DR3, DR5 |
No |
hA8 |
–16,569 |
–15,652 |
DR3, DR4 |
Yes |
hA9 |
–15,465 |
–14,992 |
DR3 |
No |
hA10 |
–13,033 |
–12,501 |
DR5 |
No |
hA11 |
–11,707 |
–11,153 |
ER8 |
No |
hA12 |
–10,575 |
–9,592 |
DR4, ER6 |
No |
hA13 |
–6,906 |
–6,347 |
DR3 |
No |
Promoter |
–1,249 |
–1 |
DR3, DR4(2x), DR5, ER6, ER8(2x) |
No |
*Relative to the ALAS1 transcriptional start site.
†
Potential nuclear receptor binding sites within each fragment that fit the selection criteria.‡
Refers to the ability of the fragment to confer drug-mediated activation in reporter gene assays.